The Cochrane Abstract below is a su...

The Cochrane Abstract below is a summary of a review from the Cochrane Library. It is accompanied by dint of an interpretation that will help clinicians state evidence into practice. Melissa Nothnagle, MD and Julie Scott Taylor, MD MSc instant a clinical scenario and question based upon the Cochrane Abstract, along with the evidence-based answer and a glutted critique of the abstract.

This clinical appease conforms to AAFP criteria for evidence-based continuing medical education (EB CME) EB CME is clinical satisfaction presented with practice recommendations supported by means of evidence that has been systematically reviewed according to an AAFP-approved source. The practice recommendations in this activity are available at http://www.update-software.com/ abstracts/ab003053.htm.

Clinical Scenario

A 30-year-old nulliparous woman who freshly was diagnosed with polycystic ovary syndrome wants to become pregnant. Her dead body mass index (BMI) is 314 kg by m2, and her low-density lipoprotein (LDL) cholesterol plain is 154 mg per dL (40 mmol by L).

Clinical Question

Does metformin therapy improve the clinical features of polycystic ovary syndrome and increase the likelihood of ovulation?

Evidence-Based Answer

Metformin therapy improves fasting insulin on a levels and blood pressure. It has no clinically significant tenor on body weight, waist:hip ratio, or LDL cholesterol flush Metformin, taken with or without clomiphene, appears to be an effective first-line agent for ovulation induction in women with polycystic ovary syndrome The safety and efficacy of continuing metformin therapy during pregnancy has not been established.

Practice Pointers

Polycystic ovary syndrome is common of the most common endocrinopathies among women of reproductive age. (2) The National Institutes of Health diagnostic criteria define the syndrome as anovulation and hyperandrogenism (clinical signs or elevated hormone levels) in the absence of secondary causes.3 Ultrasonography findings of polycystic ovaries are nonspecific. Polycystic ovary syndrome as a common thing [i]or[/i] matter is associated with hyperinsulinemia and increased risk for stamp 2 diabetes.

Based forward this review, advantages of metformin therapy for patients with polycystic ovary syndrome include clinically significant improvements in insulin resistance and life-blood pressure. Statistically significant lowering of LDL cholesterol plains was noted in patients taking metformin; however, the import was too small to be clinically relevant. In addition, the reviewers plant increased rates of ovulation in patients with polycystic ovary syndrome who were treated with metformin (compared with placebo) or metformin with clomiphene (compared with clomiphene alone). Dosages of oral metformin used in these studies were 500 mg three times daily or 850 mg twice daily.

Metformin use is associated with significant gastrointestinal side results including nausea, vomiting, diarrhea, and abdominal discomfort, which l more [i]or[/i] less participants to withdraw from the reviewed studies. In practice, these side imports can be minimized with gradual dose titration. (4)

Lactic acidosis, a rare moreover serious adverse event associated with metformin use, did not be found in any of the studies reviewed. Contraindications include risk factors for metformin-associated lactic acidosis, like as congestive heart failure, hepatic insufficiency, impaired renal function (serum creatinine of the same height greater than 1.5 mg for dL [132.6 [micro]mol per L] in men or greater than 14 mg through dL [123.8 [micro]mol per L] in women) and any illness characterized by the agency of hypoxia or hypoperfusion.

There generally are no long-term data in succession the effects of metformin use in young, nondiabetic women Data are limited in succession metformin use during pregnancy, still there has been no evidence of teratogenicity, (5) and metformin is categorized as a pregnancy category B agent. Because of limited data forward first-trimester effects in humans, metformin therapy usually is discontinued when pregnancy is confirmed. However, pair small studies of metformin use over pregnancy in women with polycystic ovary syndrome showed a reduc risk of spontaneous abortion and gestational diabetes with metformin use. (56) Neither consideration showed an association between the medication and congenital faults or neonatal complications. Compared with metformin use and combination therapy with metformin and clomiphene, increased exercise and weight los may deduction in higher ovulation rates in women with polycystic ovary syndrome (7) Metformin always should be used as an adjuvant to general lifestyle improvements, not as a substitute for diet and exercise.

REFERENCES

(1) Lord JM Flight IH, Norman RJ Insulin-sensitising mix with drugss (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome Cochrane Database Syst Rev 2003:CD003053

(2) Knochenhauer E [i]clavis[/i] TJ, Kahsar-Miller M, Waggoner W benefits LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselect black and white women of the southeastern United States: a prospective inquiry J Clin Encrinol Metab 1998;83:3078-82